REHOVOT, Israel, April 11,
2024 /PRNewswire/ -- Biomica Ltd., a
clinical-stage biopharmaceutical company developing innovative
microbiome-based therapeutics and a subsidiary of Evogene
Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that it will
present results from pre-clinical studies in its irritable bowel
syndrome (IBS) program at the Digestive Disease Week (DDW)
2024 Annual Meeting. The conference is being held in
Washington, D.C., May 18-21, 2024.
The pre-clinical work was led by Prof. Yehuda Ringel, Biomica's Co-Founder and CSO, in
collaboration with the lab of Prof. Kara
Gross Margolis, at the NYU Grossman School of Medicine. In
the studies, Biomica tested two candidate therapeutic consortia of
live bacterial strains, BMC426 and BMC427. Treatment with these
drug candidates effectively reduced visceral pain, a major symptom
of IBS.
Presentation Details:
Session Type: Research Forum
Session Title: Gut Instincts: Exploring the Interplay of the
Microbiome and Gut-Brain Axis
Session Date & Time: May 18,
2024, from 8:00 AM to 9:30 AM
EDT
Presentation Title: Pain-reduction effect of a
rationally-designed live bacterial consortium for treatment of IBS
based on microbiome functional genomics analysis
Prof. Ringel, Biomica's Co-Founder and CSO, stated:
"These pre-clinical studies validate the findings of meticulous
discovery research based on high-quality human data collected
prospectively from patients with functional bowel disorders at the
University of North Carolina
(UNC) at Chapel Hill. These exciting
proof of concept results pave the way for further development of
our LBPs as an effective treatment for abdominal pain in patients
with IBS and other painful gastrointestinal conditions".
Prof. Ringel will attend the DDW conference and will be
available for in-person meetings, and those interested should be in
touch with Professor Ringel and / or with the investor or public
relations team.
About Biomica's IBS therapeutic candidates: BMC426 and
BMC427
BMC426 and BMC427, which are Live Bacterial Products (LBPs), are
rationally designed consortia designed to restore specific
functionality to a microbial community with individually selected,
cultured bacteria. BMC426 and BMC427 are comprised of bacterial
strains selected for their multiple desired functions to achieve
maximal functional activity with only 4 or 5 bacterial strains,
respectively. These LBP's are aimed to result in robust metabolic,
physiologic, and immune modulation, and affect IBS through several
underlying and complementary modes of action.
About Biomica Ltd.:
Biomica is a clinical stage biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing PRISM system, a
proprietary computational platform powered by Evogene's
MicroBoost AI tech-engine. licensed from Evogene. Biomica
aims to identify and characterize disease-related microbiome
entities and to develop novel therapeutics based on these
understandings. The company is focused on the development of
therapies for antibiotic resistant bacteria, immuno-oncology, and
microbiome-related gastrointestinal (GI) disorders. Biomica is a
subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE:
EVGN).
For more information, please visit www.biomicamed.com
About Digestive Disease Week
Digestive Disease Week® (DDW) is the largest international
gathering of physicians, researchers and academics in the fields of
gastroenterology, hepatology, endoscopy and gastrointestinal
surgery. Jointly sponsored by the American Association for the
Study of Liver Diseases (AASLD), the American Gastroenterological
Association (AGA) Institute, the American Society for
Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of
the Alimentary Tract (SSAT), DDW is an in-person and virtual
meeting from May 18-2, 2024. The
meeting showcases more than 4,000 abstracts and hundreds of
lectures on the latest advances in GI research, medicine and
technology. More information can be found at www.ddw.org.
About Evogene Ltd.:
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of
life-science-based products by utilizing cutting-edge technologies
to increase the probability of success while reducing development
time and cost. Evogene established three unique tech-engines -
MicroBoost AI, ChemPass AI, and GeneRator AI –
leveraging Big Data and Artificial Intelligence and incorporating
deep multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of products
based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
For more information, please visit www.evogene.com.
Forward-Looking Statements:
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "will", "may", "could", "expects", "intends",
"anticipates", "plans", "believes", "scheduled", "estimates",
"demonstrates", or words of similar meaning. For example, Evogene
and Biomica are using forward-looking statements in this press
release when they discuss Biomica's product candidates
potentially resulting in robust metabolic, physiologic and immune
modulation, and affecting IBS through several underlying and
complementary modes of action, as well as an effective treatment
for abdominal pain in patients with IBS and other painful
gastrointestinal conditions. Such statements are based on current
expectations, estimates, projections and assumptions, describe
opinions about future events, and involve certain risks and
uncertainties which are difficult to predict and are not guarantees
of future performance. Therefore, actual future results,
performance or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, the current war between
Israel and Hamas and any worsening
of the situation in Israel such as
further mobilizations or escalation in the northern border of
Israel and those risk
factors contained in Evogene's reports filed with applicable
securities authorities. Evogene and its subsidiaries disclaim any
obligation or commitment to update these forward-looking statements
to reflect future events or developments or changes in
expectations, estimates, projections, and
assumptions.
Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/1974949/Biomica.jpg
Logo -
https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original
content:https://www.prnewswire.com/news-releases/biomica-to-present-at-digestive-disease-week-ddw-conference-2024-annual-meeting-302114274.html
SOURCE Biomica Ltd.
